People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Pharma, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2019 |
| bluebird bio, Inc. | — | Biotechnology | Series C | $187.5M | $1.9B | 2010 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2015 |
| Faraday Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $115.5M | $829.7M | 2014 |
| OncoResponse Inc | — | Biotechnology | Series C | $109.0M | $39.3M | 2018 |
| Codiak BioSciences, Inc. | — | Biotechnology | Series C | $107.5M | $3.1B | 2015 |
| Pheast Therapeutics, Inc. | — | Pharma | Series C | $99.8M | $138.4M | 2022 |
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2015 |
| Nohla Therapeutics Inc. | — | Biotechnology | Series C | $79.4M | $1.8B | 2016 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.1M | 2015 |
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2016 |
| Theraclone Sciences, Inc. | — | Biotechnology | Series A | $36.7M | $111.3M | 2010 |
| ImmusanT, Inc. | — | Biotechnology | Series B | $32.7M | $788.8M | 2017 |
| SonoThera, Inc. | — | Biotechnology | Series B | $30.4M | $550.2M | 2022 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2010 |
| Phaserx, Inc. | — | Biotechnology | Seed | $16.1M | $18.6M | 2009 |
| Proniras Corp | — | Other | Series A | $11.2M | $37.2M | 2023 |
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
| Groove Biopharma Corp | — | Other Health Care | Series A | $8.4M | $90.8M | 2010 |
| Allozyne Inc | — | Biotechnology | Seed | $8.2M | $108.9M | 2012 |
| Nexgenia Inc. | — | Biotechnology | Seed | $4.1M | $5.3M | 2015 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2010 |
Steven Gillis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Gillis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Gillis | 3 | 13 |
| Thong Le | 3 | 12 |
| SCOTT ROCKLAGE | 3 | 9 |
| Terrance McGuire | 3 | 9 |
| Carl Weissman | 3 | 8 |
| Lindsay Rayle | 3 | 7 |
| Michael Steinmetz | 3 | 4 |
| Asish Xavier | 2 | 18 |
| Wende Hutton | 2 | 16 |
| Chad Waite | 2 | 11 |
| Michael Higgins | 2 | 9 |
| PAUL SEKHRI | 2 | 7 |
| Robert Clarke | 2 | 7 |
| Brad Smith | 2 | 6 |
| Kurt Graves | 2 | 5 |
| Clifford Stocks | 2 | 5 |
| Jeff Baxter | 2 | 4 |
| Jeffrey Leiden | 2 | 4 |
| David E. Anderson | 2 | 3 |
| Egidio Nascimento | 2 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.